for some odd reason, this didn't get on this board when I posted it earlier....let's try again:
MEDIA CONTACT: INVESTOR
Geert Kersten RELATIONS:
Chief Executive Officer Daryll Strahl
CEL-SCI Corporation (970) 377-2216
(703) 506-9460
CEL-SCI CORPORATION FORMS NEW COMPANY
VIENNA, VA, SEPTEMBER 27, 1999: CEL-SCI CORPORATION (AMEX: HIV; Berlin Stock Exchange: LSR) announces that it has formed a separate entity, called MaxPharma, to develop its L.E.A.P.S.---------------------------------------------------------------------------------------------------------------------"! -t-e-c-h-n-o-l-o-g-y-.- - -T-h-i-s- -n-e-w- -s-t-r-u-c-t-u-r-e- -a-l-l-o-w-s- -t-h-e- -C-o-m-p-a-n-y- s- -m-a-n-a-g-e-m-e-n-t- -t-o- -c-o-n-c-e-n-t-r-a-t-e- -m-o-r-e- -o-n- -i-t-s- -l-e-a-d-i-n-g- -d-e-v-e-l-o-p-m-e-n-t-a-l- -p-r-o-d-u-c-t-,- -M-u-l-t-i-k-i-n-e-(-,- -w-h-i-c-h- -i-s- -c-u-r-r-e-n-t-l-y- -b-e-i-n-g- -e-v-a-l-u-a-t-e-d- -i-n- -h-u-m-a-n- -c-l-i-n-i-c-a-l- -t-r-i-a-l-s- -i-n- -s-i-x- -c-o-u-n-t-r-i-e-s-.- - -
-
-L-.-E-.-A-.-P-.-S-.- -a-c-t-i-v-a-t-e-s- -t-h-e- -i-m-m-u-n-e- -s-y-s-t-e-m- -in specific and potent ways to fight cancer, infectious diseases and autoimmune diseases. The technology has three unique characteristics: 1) strong, specific activation of the T-cell response, as shown in animal models; 2) fast and efficient integration of selected epitopes (specific immune
triggers ) from a variety of sources; and, 3) ability to facilitate disease antigen presentation and to direct immune response outcome, a major breakthrough. The L.E.A.P.S. technology is patent protected in key markets.
Geert Kersten, Chief Executive Officer of CEL-SCI, said,
We believe that both L.E.A.P.S. and Multikine will benefit from this dedicated focus and that this transaction will ultimately increase shareholder value.
As part of the creation of MaxPharma, the Company is in discussion with a variety of third parties with the view to their eventual involvement in the financing and future success of MaxPharma. CEL-SCI intends to retain a significant share in MaxPharma!s equity. The precise structure of MaxPharma will be decided upon consultation with the outside investor(s).
The creation of MaxPharma enables CEL-SCI to focus both management time, as well as its financial resources, on the future development of Multikine. Multikine!s most extensive current development covers its evaluation as a pre-surgical regimen in patients with head and neck cancer.
CEL-SCI Corporation is a biopharmaceutical company whose mission it is to use the immune system to combat disease.
# # #
``CEL-SCI press releases are available through Company News On-Call by fax, 800-758-5804,
Ext. 445563, or at HYPERLINK "http://www.cel-sci.com"http://www.cel-sci.com on the Internet.'
When used in this report, the words "intends," "believes," "anticipated" and "expects" and similar expressions are intended to identify forward-looking statements. Such statements are subject to risks and uncertainties which could cause actual results to differ materially from those projected. Factors that could cause or contribute to such differences include, an inability to duplicate the clinic results demonstrated in preclinical studies, timely development of any potential products that can be shown to be safe and effective, receiving necessary regulatory approvals, difficulties in manufacturing any of the Company's potential products and the risk factors set forth from time to time in CEL-SCI Corporation's SEC filings, including but not limited to its report on Form 10-K for the year ended September 30, 1998. The Company undertakes no obligation to publicly release the result of any revision to these forward-looking statements which may be made to reflect the events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.
------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------ |
